RxMx uses systems innovation to re-engineer risk management strategies and patient support for medicines. With origins in Australia, RxMx also operates in the US & Europe.
Traditionally, medicine has been slow to adopt the scale of productivity improvements that other industries take for granted. Our platforms use automated technologies to bridge the gap between pharmaceuticals and real-world risk mitigation; deliver enhanced, efficient patient support programs; and to manage integrated patient reported outcome studies.
Founded by four specialist physicians, our driving philosophy is developing medical systems that ensure the safe delivery of complex and sophisticated medicines, with minimal burden on physicians and patients.
RxMx offers an innovative suite of medical solutions that enhances the quality use of medicines, optimising patient safety and delivering real-world efficiency in busy clinical settings.
We offer healthcare organisations three programs that support the use of medicines
RiskMx platform for automated monitoring, alerting and RMP implementation
Technology-enabled Patient Support Programs
MOD (MObile Data) Patient Reported Outcomes (PRO) platform
All the company’s platforms are compliant with regulatory standards for computerised systems, including CFR 21 Part 11; and have at their core an advanced database management system that facilitates the automated, reliable analysis of complex datasets at lightning fast speed.
The RiskMx platform, developed and tested in a clinical trial, bridges the gap between pharmaceuticals and risk mitigation and is built for customisation to any medicine. At its heart, the RiskMx core continuously monitors pathology and other patient-level data using pre-defined algorithms that provide the basis for automated, real-time, healthcare practitioner-friendly REMS/RMP implementation. RiskMx is a transformative technology that adds a robust layer of medicine safety for patients, prescribers and the pharmaceutical industry.
The Bloodwatch Monitoring service is a novel, automated solution designed by to implement the risk management plan and associated monitoring for Lemtrada® (alemtuzumab), a disease-modifying treatment for multiple sclerosis.
The MOD (MObile Data) platform is specifically designed to manage PRO studies. It provides a completely automated pipeline using web, SMS and email technologies to generate aggregated, cumulative trial datasets in real-time, without human intervention.